Next-Generation Molecular Diagnostics Development by CRISPR/Cas Tool: Rapid Detection and Surveillance of Viral Disease Outbreaks

Virus disease spreads effortlessly mechanically or through minute insect vectors that are extremely challenging to avoid. Emergence and reemergence of new viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), H1N1 influenza virus, avian influenza virus, dengue virus, Citrus t...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in molecular biosciences Vol. 7; p. 582499
Main Authors Srivastava, Sonal, Upadhyay, Dilip J, Srivastava, Ashish
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.12.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Virus disease spreads effortlessly mechanically or through minute insect vectors that are extremely challenging to avoid. Emergence and reemergence of new viruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), H1N1 influenza virus, avian influenza virus, dengue virus, Citrus tristeza virus, and Tomato yellow leaf curl virus have paralyzed the economy of many countries. The cure for major viral diseases is not feasible; however, early detection and surveillance of the disease can obstruct their spread. Therefore, advances in the field of virus diagnosis and the development of new point-of-care testing kits become necessary globally. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) is an emerging technology for gene editing and diagnostics development. Several rapid nucleic acid diagnostic kits have been developed and validated using Cas9, Cas12, and Cas13 proteins. This review summarizes the CRISPR/Cas-based next-generation molecular diagnostic techniques and portability of devices for field-based utilization.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Sangeeta Chakraborty, National Jewish Health, United States; Allen Thayakumar Basanthakumar, Dana–Farber Cancer Institute, United States
These authors have contributed equally to this work
Edited by: Megha Agrawal, University of Illinois at Chicago, United States
This article was submitted to Molecular Diagnostics and Therapeutics, a section of the journal Frontiers in Molecular Biosciences
ISSN:2296-889X
2296-889X
DOI:10.3389/fmolb.2020.582499